Montelukast-induced generalized urticaria

Annals of Pharmacotherapy

Volumn 38, Issue 6, 2004, Pages 999-1001

  Minciullo, Paola L ^a   Saija, Antonella ^a   Bonanno, Domenica ^a   Ferlazzo, Edoardo ^a   Gangemi, Sebastiano ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Montelukast; Urticaria

Indexed keywords

BETAMETHASONE; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST;

ADULT; ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; CASE REPORT; DRUG WITHDRAWAL; EYELID EDEMA; HUMAN; MALE; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SKIN MANIFESTATION; SYMPTOMATOLOGY; URTICARIA;

ACETATES; ADULT; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; QUINOLINES; URTICARIA;

EID: 2442682132     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D547     Document Type: Article

References (16)

1. CCMRC/GlNA. Workshop on asthma management and prevention in the Caribbean. July 1-3, 1997. Trinidad. Commonwealth Caribbean Medical Research Council. Global Initiative for Asthma. West Indian Med J 1998 Dec;47(suppl 4):133-52.
2. Balzano G, Fuschillo S, Gaudiosi C. Leukotriene receptor antagonists in the treatment of asthma: an update. Allergy 2002;57(suppl 72):16-9.
3. Reiss TF, Altman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
4. 4-receptor antagonist, in healthy volunteers. Br J Clin Pharmacol 1995;40:277-80.
5. Romero-Gomez M, Sanchez-Muñoz D, Castilla L, Castor M. Acute hepatitis due to montelukast (letter). Med Clin (Barc) 2003;120:239.
6. Margery J, Dot JM, Bredin C, Bonnichon A, Romand F, Guigay J, et al. Montelukast induced cytolytic acute hepatitis (letter). Gastroenterol Clin Biol 2003;27:129-30.
7. Sass DA, Chopra KB, Wu T. A case of montelukast-induced hepatotoxicity. Am J Gastroenterol 2003;98:704-5.
8. Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? Drug Saf 1999;21:241-51.
9. Jamaleddine G, Diab K, Tabbarah Z, Tawil A, Arayssi T. Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum 2002;31:218-27.
10. Nettis E, Pannofino A, Cavallo E, Ferrannini A, Tursi A. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria (letter). J Allergy Clin Immunol 2003;112:212-3.
11. Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002;110(suppl 3):484-8.
12. Hani N, Hartmann K, Camper C, Peters T, Schneider LA, Hunzelmann N, et al. Improvement of cold urticaria by treatment with the leukotriene receptor antagonist montelukast (letter). Acta Derm Venereol 2000;80:229.
13. Gal AA, Morris RJ, Spraker MK. Cutaneous lesions of Churg-Strauss syndrome associated with montelukast therapy (letter). Br J Dermatol 2002;147:618-9.
14. Solans R, Bosch JA, Selva A, Orriols R, Vilardell M. Montelukast and Churg-Strauss syndrome. Thorax 2002;57:183-5.
15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
16. Kilpio K, Hannuksela M. Corticosteroid allergy in asthma. Allergy 2003;58:1131-5.